Sign in

    Ivan Hosinov

    Senior Equity Analyst at Vladimir Pharma

    Ivan Hosinov is a Senior Equity Analyst at Vladimir Pharma, specializing in pharmaceutical and biotechnology company research with a primary focus on Eastern European markets. He covers major companies such as Biogen, Novartis, and Yandex Pharma, and is recognized for maintaining an impressive recommendation success rate above 68% on investment platforms, generating an average annual return of 15% for his covered stocks. Hosinov began his career at AlfaInvest in 2014 as a junior analyst before joining Vladimir Pharma in 2018, and has since advanced to his current senior position thanks to his evidence-driven analysis and consistent outperformance against sector benchmarks. He is FINRA Series 7 and Series 63 licensed, underscoring his professional rigor and depth of market knowledge.

    Ivan Hosinov's questions to CAPRICOR THERAPEUTICS (CAPR) leadership

    Ivan Hosinov's questions to CAPRICOR THERAPEUTICS (CAPR) leadership • Q2 2025

    Question

    An analyst from Vladimir Pharma asked for clarification on the BLA review timeline post-resubmission, the rationale for selecting LVEF as the primary endpoint, and the implications of recent events for the Becker Muscular Dystrophy (BMD) program.

    Answer

    CEO Linda Marbán explained that the review timeline is a key topic for the FDA meeting. She justified the LVEF endpoint by citing recent studies that established its link to clinical outcomes in DMD, making it a relevant primary endpoint. She stated that plans for the BMD program are paused until there is clarity on the path forward for deromyocel in DMD.

    Ask Fintool Equity Research AI